Margaret Macro

13.5k total citations · 1 hit paper
83 papers, 3.6k citations indexed

About

Margaret Macro is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Margaret Macro has authored 83 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Hematology, 38 papers in Oncology and 33 papers in Molecular Biology. Recurrent topics in Margaret Macro's work include Multiple Myeloma Research and Treatments (47 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (14 papers). Margaret Macro is often cited by papers focused on Multiple Myeloma Research and Treatments (47 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (14 papers). Margaret Macro collaborates with scholars based in France, United States and Belgium. Margaret Macro's co-authors include Gérald Marit, Hervé Tilly, Bertrand Coiffier, Dominique Bordessoule, Sylvie Castaigné, Karim Belhadj, Catherine Thiéblemont, Christophe Fermé, Isabelle Plantier and Catherine Sebban and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Margaret Macro

79 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

2010 1.1k citations Bertrand Coiffier, Catherine Thiéblemont et al. Blood profile →

Peers

Countries citing papers authored by Margaret Macro

Since Specialization

Citations

This map shows the geographic impact of Margaret Macro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Macro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Macro more than expected).

Fields of papers citing papers by Margaret Macro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Macro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Macro. The network helps show where Margaret Macro may publish in the future.

Co-authorship network of co-authors of Margaret Macro

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret Macro. A scholar is included among the top collaborators of Margaret Macro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret Macro. Margaret Macro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma 2024 ·Blood ·Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie‐Lorraine Chrétien, Lionel Karlin, Martine Escoffre, (unknown), Mourad Tiab, Xavier Leleu, Hervé Avet‐Loiseau, (unknown), Lucie Planche, Jill Corre, Philippe Moreau	28
2	All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D. 2024 ·Journal of Clinical Oncology ·Cyrille Touzeau, Xavier Leleu, Mourad Tiab, Margaret Macro, Aurore Perrot, Julie Gay, Carine Chaleteix, Murielle Roussel, Lionel Karlin, (unknown), Salomon Manier, Cyrille Hulin, Olivier Decaux, Valentine Richez, Thomas Chalopin, Mohamad Mohty, Hervé Avet‐Loiseau, Lucie Planche, Jill Corre, Philippe Moreau, (unknown)	1
3	Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study 2023 ·Annals of Hematology ·Margaret Macro, Cyrille Hulin, Laure Vincent, (unknown), Lotfi Benboubker, (unknown), A.-M. Stoppa, Kamel Laribi, (unknown), (unknown), (unknown), Valentine Richez, F. Maloisel, Lionel Karlin, (unknown), C. Chouaïd, Xavier Leleu	6
4	Hairy cell leukaemia with unusual BRAF mutations 2023 ·Journal of Cellular and Molecular Medicine ·Elsa Maître, Margaret Macro, Xavier Troussard	11
5	Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group 2023 ·Thrombosis Research ·Laurent Frenzel, Olivier Decaux, Margaret Macro, (unknown), Salomon Manier, Cyrille Touzeau, Xavier Leleu, Corinne Frère, Thomas Lecompte, Aurore Perrot, Hervé Avet‐Loiseau, Philippe Moreau, Émilie Chalayer	13
6	Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma 2023 ·Frontiers in Oncology ·Laura Rosiñol, Benjamin Hébraud, Albert Oriol, (unknown), (unknown), Cyrille Hulin, María Jesús Blanchard, Denis Caillot, Anna Sureda, Miguel‐Teodoro Hernández, Bertrand Arnulf, María‐Victoria Mateos, Margaret Macro, Jesús F. San Miguel, Karim Belhadj, Juan José Lahuerta, (unknown), Joan Bladé, Philippe Moreau	5
7	Déclaration des erreurs médicamenteuses dans les recherches portant sur le médicament : place du pharmacien des essais cliniques ? 2021 ·Therapies ·(unknown), (unknown), Margaret Macro, Pascale Olivier, (unknown), (unknown), (unknown), Nadine Petitpain, Charlotte Müller, (unknown), (unknown), François Fournel, (unknown), (unknown), Laure Peyro‐Saint‐Paul	3
8	Recommandations de l’Intergroupe francophone du myélome sur le traitement d’induction et l’entretien des patients éligibles au traitement intensif 2019 ·Hématologie ·Margaret Macro	2
9	Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma 2019 ·Blood ·Olivier Decaux, Margaret Macro, Sophie Gourgou, Florence Lachenal, (unknown), Bertrand Arnulf, Denis Caillot, Anne‐Marie Stoppa, Laure Vincent, Arnaud Jaccard, Philippe Moreau, Aurore Perrot, Mohamad Mohty, Lionel Karlin, Cécile Fohrer, Jean‐Richard Eveillard, Jean Fontan, Xavier Leleu, Cyrille Hulin, Sylvain Choquet	0
10	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study 2018 ·Clinical Cancer Research ·Clément Bailly, Thomas Carlier, Bastien Jamet, Thomas Eugène, Cyrille Touzeau, Michel Attal, Cyrille Hulin, Thierry Façon, Xavier Leleu, Aurore Perrot, Laurent Garderet, Margaret Macro, Denis Caillot, Philippe Moreau, Françoise Kraeber‐Bodéré, Caroline Bodet‐Milin	20
11	Le pomalidomide dans le myélome multiple 2015 ·La Revue de Médecine Interne ·Guillemette Fouquet, Margaret Macro, O. Decaux, Cécile Fohrer, Stéphanie Guidez, Hélène Demarquette, (unknown), Chloé Prodhomme, Loïc Renaud, Claire Bories, Charles Herbaux, Lionel Karlin, Murielle Roussel, Lotfi Benboubker, Cyrille Hulin, Bertrand Arnulf, Xavier Leleu	1
12	Clinical and biological features of t(4;14) multiple myeloma: a prospective study 2011 ·Leukemia & lymphoma ·Lionel Karlin, Jean Soulier, Olivia Chandesris, Sylvain Choquet, Karim Belhadj, Margaret Macro, Didier Bouscary, Raphaël Porcher, David Ghez, Marion Malphettes, Bouchra Asli, Jean Claude Brouet, Jean Christophe Bories, Olivier Hermine, Jean Paul Fermand, Bertrand Arnulf	13
13	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) 2010 ·Journal of Clinical Oncology ·Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel, Philippe Moreau, Catherine Guérin‐Charbonnel, Denis Caillot, Gérald Marit, Lotfi Benboubker, Laurent Voillat, Claire Mathiot, Brigitte Kolb, Margaret Macro, L. Campion, Marc Wetterwald, Anne‐Marie Stoppa, Cyrille Hulin, Thierry Façon, Michel Attal, Stéphane Minvielle, Jean‐Luc Harousseau	298
14	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte breakdown → 2010 ·Blood ·Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste, G. Lepeu, Isabelle Plantier, Sylvie Castaigné, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban, Karim Belhadj, Dominique Bordessoule, Christophe Fermé, Hervé Tilly	1071
15	All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) 2004 ·Annals of Oncology ·Nicolas Mounier, C Gisselbrecht, (unknown), Corinne Haïoun, Pierre Feugier, Fritz Offner, Christian Récher, Aspasia Stamatoullas, Franck Morschhauser, Margaret Macro, Catherine Thiéblemont, Anne Sonet, Bettina Fabiani, F Reyes	48
16	Prognostic factors for aggressive lymphoma patients treated with front-line autotransplantation after complete remission: A cohort study on 330 patients 2003 ·Blood ·Nicolas Mounier, Christian Gisselbrecht, Josette Brière, Corinne Haïoun, Pierre Feugier, Fritz Offner, Christian Récher, Aspasia Stamatoullas, F. Morschhauser, Margaret Macro, Catherine Thiéblemont, A Bosly, Bettina Fabiani, F Reyes	1
17	Incidence and risk factors for central nervous system occurrencein elderly patients with diffuse large-B-cell lymphoma: influenceof rituximab 2003 ·Annals of Oncology ·Pierre Feugier, J.-M. Virion, Hervé Tilly, Corinne Haïoun, Gérald Marit, Margaret Macro, Dominique Bordessoule, Christian Récher, Michel Blanc, Thierry Jo Molina, P Lederlin, Bertrand Coiffier	190
18	Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy 2000 ·European Journal of Nuclear Medicine and Molecular Imaging ·Corinne Delcambre, Oumédaly Reman, M. Henry‐Amar, (unknown), Margaret Macro, Stéphane Chèze, (unknown), A Tanguy, O. Switsers, (unknown), (unknown), M Leporrier, Stéphane Bardet	32
19	IgE Multiple Myeloma 1999 ·Leukemia & lymphoma ·Margaret Macro, Isabelle André‐Schmutz, E. Comby, S. Chèze, Françoise Chapon, J. Ballet, Oumédaly Reman, M Leporrier, Xavier Troussard	22
20	Hemibody irradiation in stage III multiple myeloma: results of 20 patients. 1988 ·PubMed ·Xavier Troussard, Alexandre Roussel, Oumédaly Reman, Margaret Macro, M Leporrier	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact